TABLE 3.
Data and characteristics of the 43 mTPE treatments provided to 17 dogs with immune‐mediated hematological disorders
| Variable | Unit | Median (IQR) N (%) |
|---|---|---|
| Total blood volume processed | mL/kg | 440 (404‐488) |
| Average blood flow rate | mL/min | 56 (33‐68) |
| Average filtration fraction | % | 15 (13‐18) |
| Replacement volume | mL | 1166 (442‐2135) |
| Plasma volume exchanged | PVE | 1.03 (1.01‐1.18) |
| Treatment duration | min | 150 (111‐198) |
| Filtration intensity | mL/min | 7.5 (4.1‐12.1) |
| Anticoagulation |
RCA: 6 (14%) RCA‐SH: 37 (86%) |
|
| Citrate infusion rate: start; average | mmol/L blood | 3.8 (3.5‐4.0); 3.9 (3.6‐4.0) |
| Heparin dose | U/kg/tx | 56 (40‐73) |
| Composition of the replacement fluid | vol% | |
| HAlb (36/43 tx, 84%) | 18% (9‐25) | |
| HES (10/43 tx, 23%) | 0% (0‐0) | |
| NaCl (29/43 tx, 67%) | 41% (21‐47) | |
| FFP (43/43 tx, 100%) | — |
Notes: Numerical data are presented as median (interquartile range [IQR]) and proportions as number (%). The fluids used as replacement of plasma included human albumin (HAlb, 5%); hydroxyethylstarch (HES, 3%); normal saline (NaCl, 0.9%); and fresh‐frozen plasma (FFP).
Abbreviations: PVE, plasma volume exchange; RCA, regional citrate anticoagulation; RCA‐SH, regional citrate anticoagulation with systemic heparinization; tx, treatment.